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Abstract 
Android and iPhones are the two most popular mobile devices today. Each of these mobile 
Operating System is constantly trying to surpass the other, both in terms of the software 
developer and the user. While each one is just as powerful as another one, they are not 
without their own exceptional disadvantages. In this article, we analyze the pros and cons of 
both Android and iPhone from the point of view of medical applications of developers and 
medical researchers. Intravenous glucose tolerance level are called as Diabetes mellitus 
syndrome which is a group of metabolic disorder disease resulting in increased blood sugar 
level, either because of the pancreas will not able to secrete enough insulin as fluid or 
because human cells will not respond or revert to the insulin produced in human body. The 
Diabetes mellitus type 2 (NIDDM) is a human metabolic disorder and which is characterized 
by the high glucose contend in the blood on context of the body insulin resistance as well as 
deficiency in the human body.Over the past few decades, the human receptors of nuclear 
family, in particular the activated receptors of peroxisome proliferator (PPARs), has 
emerged as one of the most important drug targets the metabolic syndrome.Consequently, 
compounds that activate the PPARs have served as a potential therapeutics for the treatment 
of T2DM and anomalities associated with this disorder. The present investigation has been 
designed with a focus to identify novel ligands using TZDs that could facilitate the drug 
action for T2DM. These identified ligands can be interrogated by using the developed app 
through android phone. 
 
Keywords: Molecular docking; Medical data mining; Diabetes; Android app; Virtual 
screening. 
 
INTRODUCTION 
The people of global majority are not 
aware,exactly what diabetes is. Most of 
them heard about diabetes on the news or 
through the people who has suffered 
through this worst disease however, this 
doesn‟t mean that everyone knows about 
this disease and how to manage it.Type 2 
diabetes makes up about 90% of cases of 
diabetes with the other 10% due primarily 
to diabetes mellitus type 1 and gestational 
diabetes. Obesity is thought to be the 
primary cause of type 2 diabetes in people 
who are genetically predisposed to the 
disease (Bong - Soo Cha et al., 2005). 
Abnormalities in the homeostasis of 
glucose and lipids will lead to diabetes 
mellitus, dyslipidaemia, inflammatory 
abnormalities and vascular dysfunctions, 
which are collectively known as 
„Metabolic syndrome‟. Insulin resistance 
and Obesity are the two important 
underlying causes of metabolic syndrome.  
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Chronic hyperglycaemia, a key feature of 
diabetes mellitus, can adversely affect 
various organs like heart, kidney, nerves, 
blood vessels, eye, immune system etc. 
leading to vascular complications, 
cardiopathy, nephropathy, neuropathy and 
retinopathy. Hyperglycaemia and 
dyslipidaemia coupled with inflammation 
and oxidative stress are major risk factors 
for the development of atherosclerotic 
cardio vascular disease (ASCVD) (Roy 
Eldoret al.2013). Diabetes and its 
associated conditions pose severe 
challenge to the global health. According 
to a recent estimate, more than 288 million 
people were affected by diabetes in 2015 
and the number is expected to increase by 
54% in just 20 years.These scenarios are 
quantum jump on burden of the global 
economy by means of expenses on 
diabetes research, diagnosis and 
management. Although to address these 
issues a number of drugs are currently 
available to control metabolic disorders of 
the diabetes II but still the issue remains 
insolvable and unconquered. Depending 
on the needs of the individual, android 
health apps can be very beneficial, 
especially from the standpoint of possible 
support. However, the person choosing the 
android App needs to consider what they 
want or needs to track as well as how safe 
in health wise they are. First Step in this 
process of developing android apps choice 
should be to narrow down the apps based 
on individuals to track blood glucose and 
learn about their patterns through 
molecular modeling and docking.With the 
developed android app, one  can connect 
with friends and family to know how they 
are  doing and for a great motivational 
system.The developed app will allow the 
people to see blood pressure and vital 
signs along with its own diary including 
trends for what spikes the diabetes and 
energy level of human body. 
The Android OS 
The android is an open source mobile 
operating system intended to run on a 
range of mobile devices, ranging 
across different mobile device brands and 
different models. Android is an actual 
cellular phone Operating System and not 
merely a mobile phone devise. Android 
application is more dynamic in the sense 
that, the manufacturers may license the 
Operating System for any devices of their 
interest and also make some modifications 
in the OS as their preferred requisite. 
There will be no centralized manufacturer 
with Android mobile app as in the case of 
Apple I phone. The developer has number 
of online Android mobile software sources 
to select from, or and apart from the main 
Android manufacturing and distribution 
Market. While Android applications help 
the producer and software developer 
provides the user to the greater amount of 
models and application features, the 
problem is, that the Operating System 
software is highly fragmented, so that it, 
becomes much more complex in nature. 
Also, testing medical applications gets that 
much of simpler with a lot less Operating 
System versions to be dealt with. The 
iPhone and Android mobile phones are 
basically excellent devices, each of those 
having its own feedback and drawbacks. 
Anyway, both software developers and 
medical scientists must analyze fully the 
prospectus and configuration of each 
mobile platform before developing or 
approving medical application software for 
the devices. 
 
Peroxisome proliferator - activated 
receptors (PPARS) 
In this present investigation the chosen 
peroxisome and proliferator activated 
receptors of(PPARs) are form a gang of 
nucleotide receptors protein and drug 
molecules that are mainly functioning as a 
transcript model factors and they are 
regulating mechanism in the gene 
expression of genetically arranged 
manipulation.The PPARs ligands play 
main and important key roles in the 
regulatory mechanism of cellular 
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modification and differentiation. In to the 
development, the metabolic state 
(carbohydrate, lipid, protein) and 
tumorigenesis of the higher number of 
organisms (Berger J, Feige JN et al., 
2002). The nucleotide receptor peroxisome 
proliferator activated receptor vizgamma 
(PPARγ) has emerged from a relatively 
slow and smart beginning as a regulatory 
factor adipocyte improvement and 
development to become a potential and 
important therapeutic drug target for deal 
with the diverse group of medical 
disorders, including the type II diabetes 
class of the dyslipidaemia and  
inflammation and malignancy.  
 
Peroxisome proliferator-activated receptor 
(PPAR) belongs to the nuclear hormone 
receptor (NHR) superfamily. Three 
subtypes, PPARα, PPARγ and PPARδ, for 
this receptor have been identified and 
found to be important targets for the 
treatment of type 2 diabetes, dyslipidemia, 
atherosclerosis, etc. It is now accepted that 
there are three related but quite distinct 
PPAR proteins, PPAR -α , PPAR-δ (also 
called PPAR β , Nuc-1, or FAAR), and 
PPARγ. Interestingly, two forms of the 
protein, γ1 and γ2, exist as products of 
alternative promoter usage. The two forms 
differ in that PPARγ 2 has an NH2 
terminal extension of 30 amino acids 
(Tejprakash Singh et al., 2013). In 
addition, PPARγ 2 is found selectively in 
fat tissue, whereas γ1 is expressed at low 
levels in many tissues.  All three PPAR 
subtypes bind to DNA as obligate 
heterodimers with the nuclear receptors for 
9-cis retinoic acid (RXRα, RXRβ or 
RXRγ), having the RXRα receptor as the 
preferential partner for the PPARγ receptor 
(TM Larsen et al., 2003). The selected 
DNA-binding site (called peroxisome 
proliferator-activated receptor response 
element, PPRE) in each class of the 
PPAR/RXR heterodimers are directly 
repeat of the compensating sequences of 
AGGTCA, which separated by a single 
nucleotide spacer molecule. 
 
A key report that led to identiﬁcation of 
TZDs as ligands for PPAR-γ came from 
Harris and Kletzien in 1994. Importantly, 
the TZDs were also shown to be highly 
selective for PPAR-γ, as they had very 
minimal activity toward PPAR-α or 
PPAR-δ. The identified PPARγ agonists 
andt hiazo-lidinediones are the potential 
insulin drug sensitizers, which enhances 
the insulin secretion and improves the 
glucose tolerance level through 
metabolism. The ligands of Thia 
zolidinedione - mediated to improving he 
insulin sensitivity in T2DM is 
actedthrough the multiple metabolism of 
PPARγ induced activation and enhanced 
insulin channeling and signaling which 
increased sugar transport as glucose and 
enhanced glycogen synthesis in human 
body to improve the mitochondrial 
activities and fat mobilization out of 
muscular/liver function i.e., reversal 
function of lipo-toxicity (Naoto Kubota et 
al,. 2006). The latest survey and research 
studies suggested that the metabolic effects 
and changes of thiazolidinediones are 
coordinated by mitochondrial  channeling 
namely MTOT1 and MTOT2 as they are 
represented the pyruvate transporter in 
human metabolism. The evidence that 
PPARγ is the major receptor mediating the 
anti-diabetic activity of the TZDs is now 
very strong, based on the following 
multiple lines of pharmacological evidence 
(Alarcón de la Lastra C. et al., 2004). 
 Every TZD drug molecule binds and 
activates PPARγ in the same level of 
concentration range that    has anti-
diabetic activity. 
 In many of the TZDs surveyed, the 
rank order of potentiality of their anti 
diabetic activity of molecule is closely 
matches the rank order of drugs 
affinities toPPARγ (Prasanna A. 
Dataret al. 2012). 
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 Potential and selective ligand of the 
PPARγ outside of the TZD segment 
has been developed on the basis of 
their own activation of PPARγ. These 
have anti-diabetic identity actions in 
pre-clinical prototype models of 
insulindrug resistance and diabetes. 
 Stimulated Ligands of RXR, the hetero 
dimeric partner of PPARγ, has 
developed insulin sensitivity in vivo 
(Hebe N. Gouda et al.,2009).  
 None of the receptor for the TZD drugs 
class has been identiﬁed so far. 
 
Radiolabeled TZD ligands have enabled 
development of a displacement assay that 
allowed a search for natural ligands of 
PPARγ (H.H. Parekh et al., 2004). The 
disorienting activators of all ligands of the 
PPAR family are numbers of fatty acids 
which are marked as the PPARs are 
mainly involved in lipid based metabolic 
activities. PPAR regulates certain kinds of 
gene expressions in a series such as the 
fatty amino acidsas cluster of demarcation 
(CD36), lipoprotein lipase of human 
metabolism, sterol-responsive a element-
binding protein-1c of human body and 
perilipin as protien, that promote lipid 
consumption and synthesis finally leads to 
storage in cells (MisakiIwashita et 
al.,2012). More recently, several 
polyunsaturated fatty acids, such as 
linoleic acid, have also been found to bind 
directly to PPARγ. 
 
Molecular docking 
The molecular modeling and docking is a 
method of tool which predicts normally 
the preferred arrangements of selected 
molecules to another one molecule when 
combined to each other to form new stable 
and strong complex ligands (Nolte et al., 
2006). The better understanding of the 
preferred arrangements in turn may be 
used to find the strength of associated 
ligands or binding affinity between two 
molecules by using the scoring functions. 
The molecular Docking tool is very useful 
for predicting the affinity of small drug 
molecules to the protein based ligands in 
order to estimate the affinity level and the 
complete activities of the small molecules 
in the metabolic channels.Hence molecular 
docking plays an important role in the 
molecular design of drug elements (Holger 
Gohlke et al., 2000). 
 
Molecular docking tool is one which 
considered as a problem of “lock-and-
key”, where one is interested to investigate 
the correct orientation of the 
“key”whichhelp to open the “lock” Here, 
the protein can be considered as the “lock” 
and the ligand can considered as a “key”. 
The Molecular docking tool may be 
defined as an orientation and 
optimizationtechnique used in genetics, 
which would reveals the “best-fit” method 
of a ligand that binds to a particular 
protein of interest. However, since both 
the ligand and the protein are flexible, a 
“hand-in-glove” analogy is more 
appropriate than “lock-and-key” (Kitchen 
DB et al., 2004). There are two different 
methods and approaches are popular in the 
field of the molecular docking technique. 
The first approach has been used to match 
the technique which describes the level of 
protein and the ligandspresent as balancing 
surfaces (Wei BQ, Meng EC et al., 2004). 
The another approachto simulates the 
actual docking process of gene in which 
the ligand-proteins pair wise interaction 
and energies are estimated (Morris.G M. et 
al., 1998).The MolecularDocking will be 
performed where the energy evaluation is 
combined through the grids of affinity 
potential employed various search 
algorithms to find the correct binding 
position for a ligands on a chosen protein. 
While molecular docking, the polar 
hydrogen‟s will be attached to the ligands. 
Docking was performed normally by using 
the tool Autodock 4 (Feig M et al., 2004), 
which combines all the  energy evaluations 
through the grids of affinity potential 
employing various search algorithms to 
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find the exact binding position of a protein 
ligand on a chosen protein (Morris et al., 
1998). While docking, polar hydrogen‟s 
were added to ligands using the 
hydrogen‟s module in Autodock tool and 
thereafter, Kollman united atom partial 
charges were assigned (Darko Butina et 
al., 2002). Docking of PPAR to ligands 
was carried out using LGA with standard 
docking protocol on the basis a population 
size of 150 randomly placed individuals; a 
maximum number of 2.5 *107 energy 
evaluations, a mutation rate of 0.02, a 
crossover rate of 0.80 and an elitism value 
of 1. Some independent molecular docking 
runs were carried out for each ligand and 
results were clustered as data mining 
according to the 1.0 Ǻ rmsd criteria. The 
grid maps representing the proteins were 
calculated by using auto grid and grid size 
was set to 60*60*60 points with grid 
spacing of 0.375 Ǻ. The coordinate of the 
docked protein along with the ligand was 
visualized using UCSF chimera (Pettersen 
EF et al., 2004) within 6.5 Ǻ region. 
 
MATERIALS AND METHODS 
Extraction of PDB structure of PPAR 
gamma 
PDB stands for protein data bank 
(www.pdb.org), the sole international 
repository of all   published 3D macro 
molecular structure data such as proteins 
and nucleic acids. PDB ID of PPAR gamma 
protein is 2PRG which is regarded as the 
target site for the anti-diabetic activity. 
 
Substrate selection 
More than five hundred structures of 
thiazolidine were chosen based on 
screening from the Chem Bank. The 
selected ligands are having very good 
stability and structural diversity by means 
of the bound ligands present in the 
thiazolidine crystal structure. The 
structures of selected ligands are used to 
docking function from the chem-bank 
protein and molecule compound databases 
and the Ligands were recognized and 
accepted as per the pharmacokinetic 
parameter and solubility during 
metabolism. The active site i.e. HIS 323 in 
the protein interacts with ligands of the 
substrate and gives rise to the catalytic 
activity to test ligands that helps in 
determining the binding pattern of the 
ligands to the active site of Thiazolidine 
(PPARγ) (PDB.ID: 2PRG).
 
 
(a)                (b) 
 
Fig 1.(a) - Chemical structure of Thiazolidine(b) - 3D Structure of Thiazolidine 
 
Thiazolidine is a class of heterocyclic 
organic compounds with a 5-membered 
saturated ring with a thio ether group and 
an amino group in the 1 and 3 positions 
respectively. It‟s a sulfur analogue of 
oxazolidine. Thiazolidines may be 
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synthesized by the condensation reaction 
between a thiol and an aldehyde or a 
ketone. The reaction is reversible. 
Therefore, many thiazolidines are liable 
towards the hydrolysis in the aqueous 
solution. 
For Molecular docking 
The following steps were carried out for 
molecular docking: 
 Select 2PRG protein from the read 
molecules option in the File menu. 
 The protein was modified by the 
addition of polar only hydrogen atoms, 
Kollman charges, AD4 type atoms were 
assigned to the protein molecule
 
 
Fig2.Autodock window for molecular docking 
 
 The modified molecule was saved in 
PDBQT format. 
 The entire 500 ligand molecules were 
prepared one by one for docking. 
 Initially the torsion root was detected 
and chosen for the ligand molecule. 
 This modified ligand molecule was 
also saved in PDBQT format. 
 Then the macromolecule and ligand 
were re-loaded on to the working 
window for obtaining grid parameter 
file from the grid tool bar menu. 
 Before setting up the grid box 
parameter the active site residue was 
chosen as HIS 323. 
 The grid box was generated by 
selecting a particular atom and 
parameters were setup to the 
dimensions of 60, 60, and 60 
corresponding to x, y, z coordinates. 
 The grid output was saved as 
2PRG.gpf. 
 Now macromolecule and the 
respective ligand were chosen from 
docking menu. 
 Using Lamarckian genetic algorithm 
(LGA), the output was obtained and 
saved as 2PRG.dpf. 
The GLG file and DLG file (run 
docking algorithm) was obtained using 
cygwin. Cygwin software was opened 
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and the following commands were 
given: 
 ./autogrid4.exe –p 2PRG.gpf –l 
2PRG.glg & 
On the successful completion of 
autodock, the following command was 
given: 
 ./autodock4.exe –p 2PRG.dpf –l 
2PRG.dlg & 
On the completion of the program both 
dlg and glg files are generated. 
 The dlg file was opened in WordPad 
and the minimum binding energy and 
the respective run was recorded for the 
corresponding molecule. Similarly a 
table for all the 500 molecules was 
prepared.  
 Now, top 21 molecules out of 500 
were selected which showed the 
least/minimum binding energies. 
Further work was done on these 21 
molecules only. 
Opened Cygwin and reached out for 
the first molecule of those top 21 
molecules. Then extracted dockings 
from DLG and typed the following 
command: 
 grep „^DOCKED‟ 2PRG.dlg | cut –c9- 
> 2PRG_run.pdbqtThen, typed  
 cut –c-66 2PRG_run.pdbqt > 
2PRG_run.pdb. 
Opened the generated 2PRG_run.pdbqt 
file and copied all the atoms of that 
particular run and pasted it into the 
original protein (2PRG.pdb) before 
end. Removed all the END BRANCH, 
BRANCH, TORSDOF, etc. if any and 
then saved it as DOCKED PROTEIN. 
PDB. The hydrogen bonds of the 
docked protein were analyzed using 
visualization tool-UCSF Chimera. 
Lipinski’s rule analysis 
The best 21 ligand molecules obtained on 
the basis of minimum binding energy were 
subjected to the Lipinski‟s rule analysis in 
Mol inspiration web server. Lipinski's 
rulesays that, in general, an orally active 
drug has no more than one violation of the 
following criteria: 
 Not more than 5 hydrogen bond donors 
(nitrogen or oxygenatoms with one or 
more hydrogenatoms). 
 Not more than 10 hydrogen bond 
acceptors (nitrogen or oxygenatoms). 
 A molecular weight under 500 daltons. 
 An octanol-water partition coefficient 
log P of less than 5. 
 
Drug likliness 
The Drug likeliness is a qualitative 
concept used in drug design for how "drug 
like" a substance is with respect to factors 
like bio availability and bioactivity. It is 
estimated from the molecular structure 
before the substance is even synthesized 
and tested using PASS online server. 
 
Previous research in the area 
The proteins mutation activities and their 
analysis on attachment to this five hundred 
pair  and base-pair segments of DNAs are  
identified as main sources of  nuclear 
factor which termed ARF6.These DNAs 
are normally bound to two different active 
sites (ARE6 and ARE7) in this introduced 
enhancer. This phenomenal DNA 
attachment activity was observed and 
earmarked only in the extracts of 
molecules which are termed as fat cells. 
Duplicating and cloning of this functional 
factor exposed to be a associated part of 
the peroxisome proliferator of functional 
activated molecular receptor of (PPAR) 
subfamily of nucleotide hormonal 
receptors and there are three related but 
quite distinct PPAR proteins, PPARα, 
PPARγ (also called Nuc-1, or FAAR), and 
PPARδ. PPARγ is expressed in an 
adipose-selective fashion in both rodents 
and human. Interestingly, two forms of the 
protein, γ1 and γ2, exist as products of 
alternative promoter usage. The two forms 
differ in that PPARγ2 has an NH2- 
terminal extension of 30 amino acids.It 
was earmarked as that of both the 
conventional and Lamarckian genetic 
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expression and algorithms can be handled 
ligands of more numbers of degrees of 
freedom corresponding to the replicated 
and annealing method used in the oldest 
versions of AUTODOCK tool and that the 
Lamarckian genetic expression algorithm 
is one of the most competent, effective, 
more reliable and most successful of these 
three.TZD imposed against co-crystal 
ligand (2S)-2-(4-benzylphenoxy)-3-
phenylpropanoic acid. The hydrogen bond 
network of His323, His449, and Tyr473 
interacted with the polar head of TZD. All 
lignan derivatives from nutmeg seeds was 
favorably docked against PPARγ (3HOD). 
Interestingly, macelignan gave the smallest 
of binding free energies (-11.07 kcal/mol), 
while neolignan had the highest free 
energy (FEB) (-8.00) kcal/mol. 
 
RESULT AND DISCUSSION 
Correlation was established between the 
docked score of the tested molecule with 
their pharma cokinetic parameters. The 
binding energies were in the range of -2.26 
kcal/mol to -8.80kcal/mol with minimum 
binding energy of -8.80 kcal /mol. 21 
molecules maintained essential H bond 
interaction with the binding pocket near 
His 323. Docked conformations were rated 
by a scoring functions that include terms 
for Van der Waal‟s, hydrogen bond & 
electrostatic interactions plus internal 
energy of ligands. The solubility of the 
docked compound was related with the 
binding energy with the help of the log P 
value. The ligands also showed 
hydrophobic bonds with active site residue 
HIS 323 with PPARγ. 
 
Thiazolidinediones (TZDs) are one 
important class of synthetic agonists of 
PPARγ. TZDs are anti-diabetic agents 
currently used in the treatment of T2DM 
that target adipose tissue and improve 
insulin sensitivity. Thus, our novel 
selective PPARγ agonists can act as potent 
drugs for the treatment of  hyper 
glycaemia and insulin resistance. On 
selective screening 21 TZDs- PPARγ 
agonists are characterized by making a 
hydrogen bond network with the binding 
pocket comprising of His 323 residue. 
 
More numbers of molecular drugs have 
been regularized from the class of TZDs to 
treatthe diabetes disorders like 
Rosiglitazone syndrome, Pioglitazone 
syndrome, Ciglitazone syndrome and 
many more disorder and eventhough the 
drugs available in the market shows 
additive effect with other anti – hyper 
glycemic agents which are also prone to 
show  and increase the toxicity mechanism 
during metabolic activity in cell. For 
example, Rosiglitazone shows hepato 
toxicity. Hence there is a need to find more 
potent and orally safe thiazolidine 2,4-
diones with less toxicity which made 
possible for our research work. 
 
CONCLUSION 
Based on the molecular docking we found 
that 10 compounds as of structure 
similarity of thiazolidine-4-one showed 
better binding affinities with the active site 
pocket (comprising of HIS 323) of the 
PPARγ which also act as the substrate 
binding site. All the 500 molecules were 
docked using the Auto Dock4 and were 
visualized in UCSF Chimera as shown 
above have the same orientation which 
further validate our Docking Result. The 
extension of the basic work relates to 
conventional in silicos-approaches for 
estimating and find out the attached mode 
in gene sequential order. As an extend 
there is necessity to formulate in-vitro and 
in-vivo function of the generated data to 
synthesize examining to design new 
molecular drugs with better specifications 
and metabolic activity in human cells.
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Fig 3.Visualization of docked protein (2- (3- ethoxyphenyl) - 3- (2- methoxyethyl) 1,3-  
thiazolidin- 4- one  with 2PRG) 
 
 
 
 
 
Fig4. Visualization of docked protein(5-{[cyclohexyl(2-hydroxyethyl) amino]methyl}- 2- 
thioxo- 1,3- thiazolidin- 4- one with 2PRG) 
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Lipinski’s prediction and Drug likeliness – Molecular data Mining 
 
 
 
Fig 5.   3- benzyl- 2- (2- hydroxyphenyl) - 1,3- thiazolidin- 4- one 
 
 
Fig 6.   2- (3- ethoxyphenyl) - 3- (2- methoxyethyl) - 1,3- thiazolidin- 4- one 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 7.   2- (2- phenylethyl) - 3- (pyridin- 3- ylmethyl) - 1,3- thiazolidin- 4- one 
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(a) Lipinski‟s analysis                                                    (b) Drug score 
Fig8.   2- phenyl- 3- (3- piperidin- 1- ylpropyl) - 1,3- thiazolidin- 4- one 
 
 
(a) Lipinski‟s analysis                                                          (b) Drug score                            
Fig 9.   2- phenyl- 3- (2- pyridin- 2- ylethyl) - 1,3- thiazolidin- 4- one 
 
 
Fig 10.   3- (4- hydroxyphenyl) - 2- phenyl- 1,3- thiazolidin- 4- one 
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(a) Lipinski‟s analysis                                                           (b) Drug score 
Fig11.   2- phenyl- 3- (pyridin- 4- ylmethyl) - 1,3- thiazolidin- 4- one 
 
 
 
Fig12.   (2S) - 3- benzyl- 2- (2- fluorophenyl) - 1,3- thiazolidin- 4- one 
 
 
 
Fig13.   3- benzyl- 2- (3- methyl- 2- thienyl) - 1,3- thiazolidin- 4- one 
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Fig14.2- (3- ethoxy- 4- methoxyphenyl) - 3- (2- hydroxyethyl) - 1,3- thiazolidin- 4- one 
 
 
 
 
Fig15.   2- (3- methyl- 2- thienyl) - 3- [2- (2- thienyl) ethyl]- 1,3- thiazolidin- 4- one 
 
 
 
Fig16.   5-{[cyclohexyl(2-hydroxyethyl)amino]methyl}-2-thioxo-1,3-thiazolidin-4 one 
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Fig17.  2- (2- bromophenyl) - 3- cyclohexyl- 1,3- thiazolidin- 4- one 
 
 
(a) Lipinski‟s analysis                                                          (b) Drug score 
Fig18.    2- (2- methoxyphenyl) - 3- (pyridin- 3- ylmethyl) - 1,3- thiazolidin- 4- one 
 
 
 
(a) Lipinski‟s analysis                                                         (b) Drug score 
Fig19.  2- (2- ethoxyphenyl) - 3- (2- thienylmethyl) - 1,3- thiazolidin- 4- one 
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Fig20.   3- (1,3- benzodioxol- 5- ylmethyl) - 2- isopropyl- 1,3- thiazolidin- 4- one 
 
 
 
Fig21.   2- (3- bromo- 4- fluorophenyl) - 3- (2- hydroxyethyl) - 1,3- thiazolidin- 4- one 
 
 
(a) Lipinski‟s analysis                                                        (b) Drug score                                    
 
Fig22.   2- pyridin- 3- yl- 3- (2- pyridin- 2- ylethyl) - 1,3- thiazolidin- 4- one 
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(a) Lipinski‟s analysis                                                 (b) Drug score   
Fig23.   (2S) - 3- benzyl- 2- phenyl- 1,3- thiazolidin- 4- one 
 
 
 
Fig24.3,3'- ethane- 1,2- diylbis(2- thioxo- 1,3- thiazolidin- 4- one) 
 
 
 
Fig  25.Adroid application programe (a) Programme Window: 1 - model 
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(b) Programme Window: 2 – model 
 
 
 
 
(c) Programme Window: 3 – model 
 
 
 
 
(d) Programme Window: 4 - model 
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(e) Programme Window: 5 – model 
 
 
 
(f) Programme Window: 6 - model 
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